PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

## Example Bundle: Hulafe - Bundle: Example of a Childhood Cancer Survivor Passport

Document Details

Profile: Bundle: Survivor Passport

Preliminary Document at 2025-06-11 07:41:51+0000 by Identifier: test for NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Document Subject

Language: es-ES

Profile: Patient: PCSP

NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Contact Detail | belensmicorr@gggmail.com
Language: | Spanish (Spain)
Patient Mother's Maiden Name | APELLIDO2
Patient Birth Place | CALLEFALSA123 Valencia Valencia España

Document Content

## Cancer Diagnosis and Treatment

Primary Cancer Diagnosis and Treatment Summary

### Chemotherapy

Chemotherapy Treatments

## Care Plan

Care Plan

## Additional Resources Included in Document

Entry 2 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Patient/PatientHulafe-1

Resource Patient:

> Language: es-ES

> Profile: Patient: PCSP

> NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> Contact Detail | belensmicorr@gggmail.com
> Language: | Spanish (Spain)
> Patient Mother's Maiden Name | APELLIDO2
> Patient Birth Place | CALLEFALSA123 Valencia Valencia España

Entry 3 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Condition/PrimaryCancerHulafe-1

Resource Condition:

> Language: es-ES

> Profile: Condition: Primary Cancer

> Condition Asserted Date: 2021

> Histology-Morphology-Behavior Extension: 8260/3 - Carcinoma papilar de tiroides

> code: Carcinoma tiroides

> bodySite: C73.9

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> encounter: Encounter: status = finished; class = ambulatory (ActCode#AMB)

> ### Stages

> - | Summary
> * | pT1a

> note:

> > Alergia al epitelio de gato

Entry 4 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Encounter/EncHulafe-1

Resource Encounter:

> Language: es-ES

> status: completed

> class: ambulatory

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> serviceProvider: Organization Hospital Universitari i Politècnic La Fe

Entry 5 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Ciclofosfamide

Resource MedicationAdministration:

> Profile: MedicationAdministration: Chemotherapy

> Act Location: Location Hospital la Fe

> Resource related information: Observation Cumulative dose received by a patient for a specific drug.

> status: completed

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Entry 6 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Metotrexato

Resource MedicationAdministration:

> Profile: MedicationAdministration: Chemotherapy

> Act Location: Location Hospital la Fe

> Resource related information: Observation Cumulative dose received by a patient for a specific drug.

> status: completed

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Entry 7 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Vincristina

Resource MedicationAdministration:

> Profile: MedicationAdministration: Chemotherapy

> Act Location: Location Hospital la Fe

> Resource related information: Observation Cumulative dose received by a patient for a specific drug.

> status: completed

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Entry 8 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationAdministration/ChemoHulafe-1-Citarabina

Resource MedicationAdministration:

> Profile: MedicationAdministration: Chemotherapy

> Act Location: Location Hospital la Fe

> Resource related information: Observation Cumulative dose received by a patient for a specific drug.

> status: completed

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

Entry 9 - fullUrl = http://hl7.eu/fhir/ig/pcsp/MedicationStatement/ChemoHulafe-1-corticosteroids

Resource MedicationStatement:

> Profile: MedicationStatement: Chemotherapy

> status: not-taken

> status: recorded

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> ### Dosages

> - | Timing
> * | Once

Entry 10 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Ciclofosfamide-dose

Resource Observation:

> Profile: Observation: Chemotherapy Cumulative Dose

> status: Final

> code: Cumulative dose received by a patient for a specific drug.

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> value: 3000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')

> method: Calculation technique

Entry 11 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Metotrexato-dose

Resource Observation:

> Profile: Observation: Chemotherapy Cumulative Dose

> status: Final

> code: Cumulative dose received by a patient for a specific drug.

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> value: 12000 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')

> method: Calculation technique

Entry 12 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Vincristina-dose

Resource Observation:

> Profile: Observation: Chemotherapy Cumulative Dose

> status: Final

> code: Cumulative dose received by a patient for a specific drug.

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> value: 5.4 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')

> method: Calculation technique

Entry 13 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ChemoHulafe-1-Citarabina-dose

Resource Observation:

> Profile: Observation: Chemotherapy Cumulative Dose

> status: Final

> code: Cumulative dose received by a patient for a specific drug.

> subject: NOMBRE APELLIDO1 APELLIDO2(anonymous) Female, DoB: 2005-07-01 ( urn:oid:2.16.724.4.10.50.200#123456789 (use: official, ))

> value: 920 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')

> method: Calculation technique

Entry 14 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Organization/OrgHulafe-1

Resource Organization:

> Language: es-ES

> Profile: Organization: Primary Treatment Center / Center of diagnosis

> active: true

> name: Hospital Universitari i Politècnic La Fe

> alias: La Fe

> > contact

> > telecom: +34 961 244 000, prensa_lafe@gva.es

> > address: Avinguda de Fernando Abril Martorell, nº 106 Valencia Comunidad Valenciana 46026 ES (work)

Entry 15 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Location/ChemoHulafe-1-Location

Resource Location:

> Profile: Location: PCSP

> name: Hospital la Fe

> address: Valencia Spain

Entry 16 - fullUrl = http://hl7.eu/fhir/ig/pcsp/CarePlan/CarePlanExample-1

Resource CarePlan:

> FOLLOW-UP RECOMMENDATIONS

> Here below are listed personalized follow-up recommendations, based on the treatments you received. These advices are based on international experience with people who received similar treatments as you.

> They are meant to prevent and/or diagnose at an early stage possible future complications.

> It is possible that over time these recommendations will be updated according to new clinical situations and/or new data in the scientific literature. We will make all possible efforts in order to update about any new update.

> We encourage you to report to your doctor any persistent symptom you might have, in order to allow an early identification of its cause.

> General recommendations

> A healthy lifestyle helps to maintain physical and mental wellbeing, as well as preventing possible diseases such as cardiovascular complications, tumors, and psychological problems.

> We therefore recommend you to:

> - Maintain a normal body weight and engage in regular physical activity.
> - Eat plenty of fruits and vegetables, and reduce fat, sugar, and salt intake.
> - Don't smoke and avoid excessive alcohol intake.
> - Maintain proper dental hygiene.
> - Avoid excessive sun exposure and remember to use high-protection sunscreen.
> - Check your blood pressure periodically.
> - Report to your health care provider any experience of chronic pain, excessive fatigue and/or deterioration of performance in your daily activities (study, work and/or exercise).
> - Adhere to all cancer screening programs that will be offered by the health system.

> You might be at risk of | Because you were treated with | We therefore recommend you to
> Subsequent thyroid cancer | RT to a vol exposing the thyroid gland | Counselling regarding the increased risk for developing differentiated thyroid to inform their HCP if they detect a thyroid mass (independent of the presence or absence of associated symptoms), every 5 years - Physical examination of the neck as part of a complete physical examination, whenever a survivor is assessed by a HCP - Counselling regarding options for differentiated thyroid carcinoma surveillance, at least every 5 years If the decision to commence surveillance is made, make a shared decision for one of these two surveillance modalities: - Neck palpation, every 1-2 years, starting 5 years after radiotherapy, or - Thyroid ultrasonographyw, every 3-5 years, starting 5 years after radiotherapy
> Subsequent breast cancer | RT >= 10 Gy to a vol exposing the breasts | Mammography and breast MRI every year if > 25 years of age or > 8 years from radiation, whichever occurs last
> Cardiac problems (High risk) | RT >= 35 Gy to a vol exposing the heart Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 | A physical cardiac examination at every LTFU visit, at least every 5 years. Screening for modifiable cardiovascular risk factors (hypertension, diabetes, dyslipidaemia, obesity, smoking and low levels of physical activity). - ECG once at entry into LTFU. Repeat ECG once after the age of 18 years if entry into LTFU was at a younger age. - Echocardiogram with specific attention to left ventricular systolic function, to valvular structure and function and to the pericardium, starting 2 years after treatment and at least every 2-3 years; Echocardiogram with specific attention to left ventricular function, prior to pregnancy or in the first trimester, if female - Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified Refer to a cardiologist if an abnormal ejection fraction or if other abnormalities are identified - Refer for interventions to help avert the risk of symptomatic cardiomyopathy if modifiable cardiovascular risk factors are identified

Entry 17 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-1

Resource Observation:

> Profile: Observation: Risk Factor

> status: Final

> code: Risk factor

> subject: APELLIDO1

> effective: 2022-05-12 --> (ongoing)

> value: RT to a vol exposing the thyroid gland

Entry 18 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-2

Resource Observation:

> Profile: Observation: Risk Factor

> status: Final

> code: Risk factor

> subject: APELLIDO1

> effective: 2022-05-12 --> (ongoing)

> value: RT >= 10 Gy to a vol exposing the breasts

Entry 19 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-3

Resource Observation:

> Profile: Observation: Risk Factor

> status: Final

> code: Risk factor

> subject: APELLIDO1

> effective: 2022-05-12 --> (ongoing)

> value: RT >= 35 Gy to a vol exposing the heart

Entry 20 - fullUrl = http://hl7.eu/fhir/ig/pcsp/Observation/ObservationRiskFactor-4

Resource Observation:

> Profile: Observation: Risk Factor

> status: Final

> code: Risk factor

> subject: APELLIDO1

> effective: 2022-05-12 --> (ongoing)

> value: Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2

Entry 21 - fullUrl = http://hl7.eu/fhir/ig/pcsp/DocumentReference/DocumentReferenceExample-1

Resource DocumentReference:

> Profile: DocumentReference: PCSP

> status: Current

> docStatus: Preliminary

> type: Childhood Cancer Survivor Passport

> subject: APELLIDO1

> date: 2022-06-14 13:28:17+0200

> > content

> > ### Attachments

> > - | ContentType | Language | Data | Title | Creation
> > * | application/pdf | es-ES | (base64 data - 251,792 base64 chars) | Survivor Passport of APELLIDO1 | 2022-06-14